A novel imaging agent, 68Ga-FAPI, can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. New research published ahead of print in the Journal of Nuclear Medicine shows that 68Ga-FAPI imaging offers superior lesion detection without vaccine-related tracer uptake in locoregional lymph nodes that is common with 18F-FDG imaging. This can help to prevent costly follow-up and false management decisions for cancer patients.
from Medical Xpress - latest medical and health news stories https://ift.tt/cysUZbk
